0001493152-23-017791.txt : 20230516
0001493152-23-017791.hdr.sgml : 20230516
20230516161601
ACCESSION NUMBER: 0001493152-23-017791
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230512
FILED AS OF DATE: 20230516
DATE AS OF CHANGE: 20230516
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kester Thomas J
CENTRAL INDEX KEY: 0001299870
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35731
FILM NUMBER: 23927709
MAIL ADDRESS:
STREET 1: C/O INSPIREMD, INC.
STREET 2: 321 COLUMBUS AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: InspireMD, Inc.
CENTRAL INDEX KEY: 0001433607
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 262123838
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4 MENORAT HAMAOR ST.
CITY: TEL AVIV
STATE: L3
ZIP: 6744832
BUSINESS PHONE: (888) 776-6804
MAIL ADDRESS:
STREET 1: 4 MENORAT HAMAOR ST.
CITY: TEL AVIV
STATE: L3
ZIP: 6744832
FORMER COMPANY:
FORMER CONFORMED NAME: Saguaro Resources, Inc.
DATE OF NAME CHANGE: 20080428
4
1
ownership.xml
X0407
4
2023-05-12
0
0001433607
InspireMD, Inc.
NSPR
0001299870
Kester Thomas J
C/O INSPIREMD, INC.
4 MENORAT HAMAOR ST.
TEL AVIV
L3
6744832
ISRAEL
1
0
0
0
0
Common Stock
2023-05-12
4
P
0
61249
1.6327
A
108590
D
Series H Warrants to purchase Common Stock
1.3827
2023-05-12
4
P
0
30625
1.6327
A
2023-05-15
Common Stock
30625
30625
D
Series I Warrants to purchase Common Stock
1.3827
2023-05-12
4
P
0
30624
1.6327
A
2023-05-15
Common Stock
30624
30624
D
Series J Warrants to purchase Common Stock
1.3827
2023-05-12
4
P
0
30625
1.6327
A
2023-05-15
Common Stock
30625
30625
D
Series K Warrants to purchase Common Stock
1.3827
2023-05-12
4
P
0
30624
1.6327
A
2023-05-15
Common Stock
30624
30624
D
The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").
The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.
The aggregate number of warrants reported in this row consists of 30,625 Series H Warrants that were acquired in the Private Placement.
The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial.
The aggregate number of warrants reported in this row consists of 30,624 Series I Warrants that were acquired in the Private Placement.
The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm).
The aggregate number of warrants reported in this row consists of 30,625 Series J Warrants that were acquired in the Private Placement.
The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm.
The aggregate number of warrants reported in this row consists of 30,624 Series K Warrants that were acquired in the Private Placement.
The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin.
/s/ Craig Shore, Attorney-in-Fact for Thomas J. Kester
2023-05-16